CEL-SCI Co. (CVM) Sees Large Increase in Short Interest

CEL-SCI Co. (NYSEAMERICAN:CVM) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 2,543,528 shares, a growth of 1.6% from the December 14th total of 2,504,696 shares. Based on an average daily volume of 186,318 shares, the short-interest ratio is currently 13.7 days. Currently, 9.5% of the shares of the stock are short sold.

CVM opened at $2.76 on Friday. CEL-SCI has a one year low of $0.82 and a one year high of $4.44.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in shares of CEL-SCI by 370.7% during the 3rd quarter. BlackRock Inc. now owns 603,914 shares of the company’s stock worth $2,446,000 after acquiring an additional 475,600 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of CEL-SCI by 29.7% during the 3rd quarter. Vanguard Group Inc. now owns 562,208 shares of the company’s stock worth $2,277,000 after acquiring an additional 128,764 shares during the last quarter. Vanguard Group Inc lifted its holdings in shares of CEL-SCI by 29.7% during the 3rd quarter. Vanguard Group Inc now owns 562,208 shares of the company’s stock worth $2,277,000 after acquiring an additional 128,764 shares during the last quarter. Finally, D.A. Davidson & CO. bought a new stake in shares of CEL-SCI during the 3rd quarter worth $567,000.

TRADEMARK VIOLATION NOTICE: “CEL-SCI Co. (CVM) Sees Large Increase in Short Interest” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2019/01/12/cel-sci-co-cvm-sees-large-increase-in-short-interest.html.

CEL-SCI Company Profile

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts.

Further Reading: Net Asset Value

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply